Advertisement

Journal of Computer-Aided Molecular Design

, Volume 33, Issue 9, pp 799–815 | Cite as

Discovery of a nanomolar inhibitor of the human glyoxalase-I enzyme using structure-based poly-pharmacophore modelling and molecular docking

  • Nizar A. Al-Shar’iEmail author
  • Qosay A. Al-Balas
  • Rand A. Al-Waqfi
  • Mohammad A. Hassan
  • Amer E. Alkhalifa
  • Nehad M. Ayoub
Article
  • 81 Downloads

Abstract

The glyoxalase-I (GLO-I) enzyme, which is the initial enzyme of the glyoxalase system that is responsible for the detoxification of cytotoxic α-ketoaldehydes, such as methylglyoxal, has been approved as a valid target in cancer therapy. Overexpression of GLO-I has been observed in several types of carcinomas, including breast, colorectal, prostate, and bladder cancer. In this work we aimed to identify potential GLO-I inhibitors via employing different structure-based drug design techniques including structure-based poly-pharmacophore modelling, virtual screening, and molecular docking. Poly-pharmacophore modelling was applied in this study in order to thoroughly explore the binding site of the target enzyme, thereby, revealing hits that could bind in a nonconventional way which can pave the way for designing more potent and selective ligands with novel chemotypes. The modelling phase has resulted in the selection of 31 compounds that were biologically evaluated against human GLO-I enzyme. Among the tested set, seven compounds showed excellent inhibitory activities with IC50 values ranging from 0.34 to 30.57 μM. The most active compound (ST018515) showed an IC50 of 0.34 ± 0.03 μM, which, compared to reported GLO-I inhibitors, can be considered a potent inhibitor, making it a good candidate for further optimization towards designing more potent GLO-I inhibitors.

Keywords

Glyoxalase-I Zinc binding Anticancer Poly-pharmacophore modelling Molecular docking 

Notes

Acknowledgements

This work was funded by the Deanship of Scientific Research at Jordan University of Science and Technology, Grant Number (20170288).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

10822_2019_226_MOESM1_ESM.docx (46 kb)
Supplementary file1 (DOCX 46 kb)

References

  1. 1.
    Dakin HD, Dudley HW (1913) An enzyme concerned with the formation of hydroxy acids from ketonic aldehydes. J Biol Chem 14(2):155–157Google Scholar
  2. 2.
    Thornalley PJ (1996) Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-A role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol: Vasc Syst 27(4):565–573.  https://doi.org/10.1016/0306-3623(95)02054-3 CrossRefGoogle Scholar
  3. 3.
    Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8(6):519–530CrossRefGoogle Scholar
  4. 4.
    Chen Y-L, Li Q-Z (2007) Prediction of apoptosis protein subcellular location using improved hybrid approach and pseudo-amino acid composition. J Theor Biol 248(2):377–381.  https://doi.org/10.1016/j.jtbi.2007.05.019 CrossRefPubMedGoogle Scholar
  5. 5.
    Sousa Silva M, Gomes Ricardo A, Ferreira Antonio EN, Ponces Freire A, Cordeiro C (2013) The glyoxalase pathway: the first hundred years… and beyond. Biochem J 453(1):1–15.  https://doi.org/10.1042/bj20121743 CrossRefPubMedGoogle Scholar
  6. 6.
    Guo Y, Zhang Y, Yang X, Lu P, Yan X, Xiao F, Zhou H, Wen C, Shi M, Lu J, Meng QH (2016) Effects of methylglyoxal and glyoxalase I inhibition on breast cancer cells proliferation, invasion, and apoptosis through modulation of MAPKs, MMP9, and Bcl-2. Cancer Biol Ther 17(2):169–180.  https://doi.org/10.1080/15384047.2015.1121346 CrossRefPubMedGoogle Scholar
  7. 7.
    Thornalley PJ (2003) Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy. Biochem Soc Trans 31(6):1372.  https://doi.org/10.1042/bst0311372 CrossRefPubMedGoogle Scholar
  8. 8.
    Rulli A, Carli L, Romani R, Baroni T, Giovannini E, Rosi G, Talesa V (2001) Expression of glyoxalase I and II in normal and breast cancer tissues. Breast Cancer Res Treat 66(1):67–72.  https://doi.org/10.1023/A:1010632919129 CrossRefPubMedGoogle Scholar
  9. 9.
    Mearini E, Romani R, Mearini L, Antognelli C, Zucchi A, Baroni T, Porena M, Talesa V (2002) Differing expression of enzymes of the glyoxalase system in superficial and invasive bladder carcinomas. Eur J Cancer 38(14):1946–1950.  https://doi.org/10.1016/S0959-8049(02)00236-8 CrossRefPubMedGoogle Scholar
  10. 10.
    Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T, Tsuruo T (2001) Selective activation of apoptosis program by Sp-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin Cancer Res 7(8):2513–2518PubMedGoogle Scholar
  11. 11.
    Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Naito M, Tsuruo T (2000) Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 95(10):3214–3218CrossRefGoogle Scholar
  12. 12.
    Thornalley PJ, Rabbani N (2011) Glyoxalase in tumourigenesis and multidrug resistance. Semin Cell Dev Biol 22(3):318–325.  https://doi.org/10.1016/j.semcdb.2011.02.006 CrossRefPubMedGoogle Scholar
  13. 13.
    Kreycy N, Gotzian C, Fleming T, Flechtenmacher C, Grabe N, Plinkert P, Hess J, Zaoui K (2017) Glyoxalase 1 expression is associated with an unfavorable prognosis of oropharyngeal squamous cell carcinoma. BMC Cancer 17(1):382.  https://doi.org/10.1186/s12885-017-3367-5 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hai-Tao Peng JC, Liu Tian-Yu, Yan-Qing Wu, Lin Xiao-Hong, Lai Yuan-Hui, Huang Ying-Feng (2017) Up-regulation of the tumor promoter glyoxalase-1 indicates poor prognosis in breast cancer. Int J Clin Exp Pathol 10(11):10852–10862Google Scholar
  15. 15.
    Vince R, Wadd WB (1969) Glyoxalase inhibitors as potential anticancer agents. Biochem Biophys Res Commun 35(5):593–598.  https://doi.org/10.1016/0006-291X(69)90445-8 CrossRefPubMedGoogle Scholar
  16. 16.
    Murthy NSRK, Bakeris T, Kavarana MJ, Hamilton DS, Lan Y, Creighton DJ (1994) S-(N-Aryl-N-hydroxycarbamoyl)glutathione derivatives are tight-binding inhibitors of glyoxalase I and slow substrates for glyoxalase II. J Med Chem 37(14):2161–2166.  https://doi.org/10.1021/jm00040a007 CrossRefPubMedGoogle Scholar
  17. 17.
    More SS, Vince R (2009) Inhibition of glyoxalase I: the first low-nanomolar tight-binding inhibitors. J Med Chem 52(15):4650–4656.  https://doi.org/10.1021/jm900382u CrossRefPubMedGoogle Scholar
  18. 18.
    Vince R, Daluge S, Wadd WB (1971) Inhibition of glyoxalase I by S-substituted glutathiones. J Med Chem 14(5):402–404.  https://doi.org/10.1021/jm00287a006 CrossRefPubMedGoogle Scholar
  19. 19.
    Takasawa R, Takahashi S, Saeki K, Sunaga S, Yoshimori A, Tanuma S-i (2008) Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects. Bioorg Med Chem 16(7):3969–3975.  https://doi.org/10.1016/j.bmc.2008.01.031 CrossRefPubMedGoogle Scholar
  20. 20.
    Liu M, Yuan M, Luo M, Bu X, Luo H-B, Hu X (2010) Binding of curcumin with glyoxalase I: molecular docking, molecular dynamics simulations, and kinetics analysis. Biophys Chem 147(1):28–34.  https://doi.org/10.1016/j.bpc.2009.12.007 CrossRefPubMedGoogle Scholar
  21. 21.
    Chiba T, Ohwada J, Sakamoto H, Kobayashi T, Fukami TA, Irie M, Miura T, Ohara K, Koyano H (2012) Design and evaluation of azaindole-substituted N-hydroxypyridones as glyoxalase I inhibitors. Bioorg Med Chem Lett 22(24):7486–7489.  https://doi.org/10.1016/j.bmcl.2012.10.045 CrossRefPubMedGoogle Scholar
  22. 22.
    Perez C, Barkley-Levenson AM, Dick BL, Glatt PF, Martinez Y, Siegel D, Momper JD, Palmer AA, Cohen SM (2019) Metal-binding pharmacophore library yields the discovery of a glyoxalase 1 inhibitor. J Med Chem 62(3):1609–1625.  https://doi.org/10.1021/acs.jmedchem.8b01868 CrossRefPubMedGoogle Scholar
  23. 23.
    Takasawa R, Tao A, Saeki K, Shionozaki N, Tanaka R, Uchiro H, Takahashi S, Yoshimori A, Tanuma S-i (2011) Discovery of a new type inhibitor of human glyoxalase I by myricetin-based 4-point pharmacophore. Bioorg Med Chem Lett 21(14):4337–4342.  https://doi.org/10.1016/j.bmcl.2011.05.046 CrossRefPubMedGoogle Scholar
  24. 24.
    Al-Balas Q, Hassan M, Al-Oudat B, Alzoubi H, Mhaidat N, Almaaytah A (2012) Generation of the first structure-based pharmacophore model containing a selective “zinc binding group” feature to identify potential glyoxalase-1 inhibitors. Molecules 17(12):13740–13758.  https://doi.org/10.3390/molecules171213740 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Al-Balas QA, Hassan MA, Al-Shar’i NA, Mhaidat NM, Almaaytah AM, Al-Mahasneh FM, Isawi IH (2016) Novel glyoxalase-i inhibitors possessing a “zinc-binding feature” as potential anticancer agents. Drug design, development and therapy 10:2623.  https://doi.org/10.2147/DDDT.S110997 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Al-Balas QA, Hassan MA, Al-Shar'i NA, Al Jabal GA, Almaaytah AM (2019) Recent advances in glyoxalase-I inhibition. Mini-Rev Med Chem 19(4):281–291.  https://doi.org/10.2174/1389557518666181009141231 CrossRefGoogle Scholar
  27. 27.
    Cameron AD, Olin B, Ridderström M, Mannervik B, Jones TA (1997) Crystal structure of human glyoxalase I-evidence for gene duplication and 3D domain swapping. EMBO J 16(12):3386–3395.  https://doi.org/10.1093/emboj/16.12.3386 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Cameron AD, Ridderström M, Olin B, Kavarana MJ, Creighton DJ, Mannervik B (1999) Reaction mechanism of glyoxalase I explored by an X-ray crystallographic analysis of the human enzyme in complex with a transition state analogue. Biochemistry 38(41):13480–13490.  https://doi.org/10.1021/bi990696c CrossRefPubMedGoogle Scholar
  29. 29.
    Biovia DS (2017) Discovery studio modeling environment, Pipeline Pilot Client. Dassault Systèmes, San DiegoGoogle Scholar
  30. 30.
    DeLano WL (2002) The PyMOL molecular graphics system. DeLano Scientific, San Carlos, CAGoogle Scholar
  31. 31.
    GraphPad Prism (2012). 6.01 for Windows edn., La Jolla California USAGoogle Scholar
  32. 32.
    Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, Burkhardt K, Feng Z, Gilliland GL, Iype L, Jain S, Fagan P, Marvin J, Padilla D, Ravichandran V, Schneider B, Thanki N, Weissig H, Westbrook JD, Zardecki C (2002) The protein data bank. Acta Crystallogr D 58(1):899–907.  https://doi.org/10.1107/S0907444902003451 CrossRefPubMedGoogle Scholar
  33. 33.
    Berman H (2008) The protein data bank: a historical perspective. Acta Crystallogr A 64(1):88–95.  https://doi.org/10.1107/S0108767307035623 CrossRefPubMedGoogle Scholar
  34. 34.
    Spassov VZ, Flook PK, Yan L (2008) LOOPER: a molecular mechanics-based algorithm for protein loop prediction. Protein Eng Des Sel 21(2):91–100.  https://doi.org/10.1093/protein/gzm083 CrossRefPubMedGoogle Scholar
  35. 35.
    Spassov VZ, Yan L (2008) A fast and accurate computational approach to protein ionization. Protein Sci 17(11):1955–1970.  https://doi.org/10.1110/ps.036335.108 CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Al-Shar’i NA, Hassan M, Al-Balas Q (2015) Identification of possible glyoxalase II inhibitors as anticancer agents by a customized 3D structure-based pharmacophore mode. Jordan J Pharm Sci 8(5):83–103Google Scholar
  37. 37.
    Wu G, Robertson DH, Brooks CL, Vieth M (2003) Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem 24(13):1549–1562.  https://doi.org/10.1002/jcc.10306 CrossRefPubMedGoogle Scholar
  38. 38.
    Schlick T (2002) Geometry optimization. In: von Ragué Schleyer P, Allinger NL, Clark T et al (eds) Encyclopedia of computational chemistry. Wiley, New YorkGoogle Scholar
  39. 39.
    Tirado-Rives J, Jorgensen WL (2006) Contribution of conformer focusing to the uncertainty in predicting free energies for protein−ligand binding. J Med Chem 49(20):5880–5884.  https://doi.org/10.1021/jm060763i CrossRefPubMedGoogle Scholar
  40. 40.
    Genheden S, Ryde U (2015) The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 10(5):449–461.  https://doi.org/10.1517/17460441.2015.1032936 CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Al-Balas QA, Hassan MA, Al Jabal GA, Al-Shar’i NA, Almaaytah AM, El-Elimat T (2017) Novel thiazole carboxylic acid derivatives possessing a “zinc binding feature” as potential human glyoxalase-I inhibitors. Lett Drug Des Discov 14(11):1324–1334.  https://doi.org/10.2174/1570180814666170306120954 CrossRefGoogle Scholar
  42. 42.
    Fonseca-Sanchez MA, Rodriguez Cuevas S, Mendoza-Hernandez G, Bautista-Pina V, Arechaga Ocampo E, Hidalgo Miranda A, Quintanar Jurado V, Marchat LA, Alvarez-Sanchez E, Perez Plasencia C, Lopez-Camarillo C (2012) Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade. Int J Oncol 41(2):670–680.  https://doi.org/10.3892/ijo.2012.1478 CrossRefPubMedGoogle Scholar
  43. 43.
    Hutschenreuther A, Bigl M, Hemdan NY, Debebe T, Gaunitz F, Birkenmeier G (2016) Modulation of GLO1 expression affects malignant properties of cells. Int J Mol Sci 17(12):2133.  https://doi.org/10.3390/ijms17122133 CrossRefPubMedCentralGoogle Scholar
  44. 44.
    Botta CB, Cabri W, Cini E, De Cesare L, Fattorusso C, Giannini G, Persico M, Petrella A, Rondinelli F, Rodriquez M, Russo A, Taddei M (2011) Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation. J Med Chem 54(7):2165–2182.  https://doi.org/10.1021/jm101373a CrossRefPubMedGoogle Scholar
  45. 45.
    Agrawal A, Romero-Perez D, Jacobsen JA, Villarreal FJ, Cohen SM (2008) Zinc-binding groups modulate selective inhibition of MMPs. ChemMedChem 3(5):812–820.  https://doi.org/10.1002/cmdc.200700290 CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Bohm H (1992) The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des 6(1):61–78CrossRefGoogle Scholar
  47. 47.
    Böhm H-J (1992) LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. J Comput Aided Mol Des 6(6):593–606.  https://doi.org/10.1007/bf00126217 CrossRefPubMedGoogle Scholar
  48. 48.
    Lengauer T, Rarey M (1996) Computational methods for biomolecular docking. Curr Opin Struct Biol 6(3):402–406.  https://doi.org/10.1016/S0959-440X(96)80061-3 CrossRefPubMedGoogle Scholar
  49. 49.
    Li H, Leung K-S, Wong M-H, Ballester PJ (2016) Correcting the impact of docking pose generation error on binding affinity prediction. BMC Bioinform 17(Suppl 11):308–308.  https://doi.org/10.1186/s12859-016-1169-4 CrossRefGoogle Scholar
  50. 50.
    Huang S-Y, Zou X (2007) Efficient molecular docking of NMR structures: application to HIV-1 protease. Protein Sci 16(1):43–51.  https://doi.org/10.1110/ps.062501507 CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Musoev A, Numonov S, You Z, Gao H (2019) Discovery of novel DPP-IV inhibitors as potential candidates for the treatment of type 2 diabetes mellitus predicted by 3D QSAR pharmacophore models, molecular docking and de novo evolution. Molecules 24(16):2870CrossRefGoogle Scholar
  52. 52.
    Zhu T, Cao S, Su P-C, Patel R, Shah D, Chokshi HB, Szukala R, Johnson ME, Hevener KE (2013) Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. J Med Chem 56(17):6560–6572.  https://doi.org/10.1021/jm301916b CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Loving K, Alberts I, Sherman W (2010) Computational approaches for fragment-based and de novo design. Curr Top Med Chem 10(1):14–32.  https://doi.org/10.2174/156802610790232305 CrossRefPubMedGoogle Scholar
  54. 54.
    Rees DC, Congreve M, Murray CW, Carr R (2004) Fragment-based lead discovery. Nat Rev Drug Discov 3(8):660.  https://doi.org/10.1038/nrd1467 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Medicinal Chemistry and Pharmacognosy, Faculty of PharmacyJordan University of Science and TechnologyIrbidJordan
  2. 2.Department of Clinical Pharmacy, Faculty of PharmacyJordan University of Science and TechnologyIrbidJordan

Personalised recommendations